Browse FTL

Summary
SymbolFTL
Nameferritin, light polypeptide
Aliases MGC71996; ferritin light polypeptide-like 3; L apoferritin; ferritin L subunit; ferritin light chain; ferrit ......
Chromosomal Location19q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location -
Domain PF00210 Ferritin-like domain
Function

Stores iron in a soluble, non-toxic, readily available form. Important for iron homeostasis. Iron is taken up in the ferrous form and deposited as ferric hydroxides after oxidation. Also plays a role in delivery of iron to cells. Mediates iron uptake in capsule cells of the developing kidney (By similarity).

> Gene Ontology
 
Biological Process GO:0000041 transition metal ion transport
GO:0006826 iron ion transport
GO:0006875 cellular metal ion homeostasis
GO:0006879 cellular iron ion homeostasis
GO:0006880 intracellular sequestering of iron ion
GO:0046916 cellular transition metal ion homeostasis
GO:0051235 maintenance of location
GO:0051238 sequestering of metal ion
GO:0051651 maintenance of location in cell
GO:0055072 iron ion homeostasis
GO:0055076 transition metal ion homeostasis
GO:0097577 sequestering of iron ion
Molecular Function GO:0005506 iron ion binding
GO:0008199 ferric iron binding
Cellular Component GO:0005767 secondary lysosome
GO:0005776 autophagosome
GO:0008043 intracellular ferritin complex
GO:0044754 autolysosome
GO:0070288 ferritin complex
> KEGG and Reactome Pathway
 
KEGG hsa04978 Mineral absorption
Reactome R-HSA-2173782: Binding and Uptake of Ligands by Scavenger Receptors
R-HSA-421837: Clathrin derived vesicle budding
R-HSA-432722: Golgi Associated Vesicle Biogenesis
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-917937: Iron uptake and transport
R-HSA-199991: Membrane Trafficking
R-HSA-6798695: Neutrophil degranulation
R-HSA-3000480: Scavenging by Class A Receptors
R-HSA-382551: Transmembrane transport of small molecules
R-HSA-5653656: Vesicle-mediated transport
R-HSA-199992: trans-Golgi Network Vesicle Budding
Summary
SymbolFTL
Nameferritin, light polypeptide
Aliases MGC71996; ferritin light polypeptide-like 3; L apoferritin; ferritin L subunit; ferritin light chain; ferrit ......
Chromosomal Location19q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between FTL and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between FTL and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
16222695Gestational Trophoblastic TumorPromote immunityQuantitative RNA analysis confirmed down-regulation of ferritin light polypeptide (FTL) (P = 0.037) and insulin-like growth factor binding protein 1 (IGFBP1) (P = 0.037) in HM that subsequently developed GTN when compared with those HM that regressed. Findings showed that reduced expression of genes related to cell invasion and immunosuppression, especially FTL and IGFBP1, were associated with development of GTN, and this finding may provide a better understanding of the pathogenesis of GTN.
Summary
SymbolFTL
Nameferritin, light polypeptide
Aliases MGC71996; ferritin light polypeptide-like 3; L apoferritin; ferritin L subunit; ferritin light chain; ferrit ......
Chromosomal Location19q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of FTL in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolFTL
Nameferritin, light polypeptide
Aliases MGC71996; ferritin light polypeptide-like 3; L apoferritin; ferritin L subunit; ferritin light chain; ferrit ......
Chromosomal Location19q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of FTL in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.3350.365
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.0770.989
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.5260.899
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2040.65
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.0140.997
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.4460.915
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.4260.584
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.4770.881
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.5110.89
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.4530.909
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.6160.922
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0720.488
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of FTL in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolFTL
Nameferritin, light polypeptide
Aliases MGC71996; ferritin light polypeptide-like 3; L apoferritin; ferritin L subunit; ferritin light chain; ferrit ......
Chromosomal Location19q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FTL. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolFTL
Nameferritin, light polypeptide
Aliases MGC71996; ferritin light polypeptide-like 3; L apoferritin; ferritin L subunit; ferritin light chain; ferrit ......
Chromosomal Location19q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FTL. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FTL.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolFTL
Nameferritin, light polypeptide
Aliases MGC71996; ferritin light polypeptide-like 3; L apoferritin; ferritin L subunit; ferritin light chain; ferrit ......
Chromosomal Location19q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FTL. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolFTL
Nameferritin, light polypeptide
Aliases MGC71996; ferritin light polypeptide-like 3; L apoferritin; ferritin L subunit; ferritin light chain; ferrit ......
Chromosomal Location19q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of FTL expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolFTL
Nameferritin, light polypeptide
Aliases MGC71996; ferritin light polypeptide-like 3; L apoferritin; ferritin L subunit; ferritin light chain; ferrit ......
Chromosomal Location19q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between FTL and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolFTL
Nameferritin, light polypeptide
Aliases MGC71996; ferritin light polypeptide-like 3; L apoferritin; ferritin L subunit; ferritin light chain; ferrit ......
Chromosomal Location19q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting FTL collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting FTL.
ID Name Drug Type Targets #Targets
DB00893Iron DextranSmall MoleculeFTH1, FTL, HBA1, HBB4
DB02285ProtoporphyrinSmall MoleculeFTL1
DB09147Ferric pyrophosphateSmall MoleculeFTL, HBA1, HBB3
DB09517Sodium ferric gluconate complexSmall MoleculeFTL, HBA1, HBB3
DB13995Ferric pyrophosphate citrateSmall MoleculeFTH1, FTL, HBA1, HBB4